Focusing on the Difficulty in Recurrence Rate of Bone and Soft tissue tumors, the Start-up Meeting of Key Special Project of the "14th Five-Year Plan" National Key R&D Program Held in Shanghai General Hospital

Link of the Original Article:

https://mp.weixin.qq.com/s/BPDYHbbDzNp5_vJHGhmXLA

On July 31, the start-up meeting of the project “Development of biomaterials inhibits postoperative recurrence of bone and skin tumors” was held in Shanghai General Hospital. This research project is a key project classified as “medical equipment and biomedical materials" in the national key research and development plan of the "14th Five-year plan”. Anting Wang, director of the Equipment Registration Department of Shanghai Drug Administration, Bing Shen, director of the medical  department of Shanghai Hospital Development Center, Kun Wu, director of the biotechnology and Medicine Department of Shanghai Municipal Science and Technology Commission, Xiaoqin Zeng, president and vice president of the Institute of Advanced Technology and Equipment of Shanghai Jiaotong University, Xingdong Zheng, President of Shanghai General Hospital, Yanhong Zhu, director of the Scientific Research Department at Shanghai General Hospital, Professor Jianzhong  Du of the School of Materials of Tongji University, and Professor Jingbo Yin of the School of Materials of Shanghai University, Professor Guangyin Yuan of School of Material Science and Engineering of Shanghai Jiaotong University, Professor Zhengdong Cai, the project leader, and more than 40 project team members attended the meeting.

It is reported that the project is led by Shanghai Jiao Tong University, together with biomedical companies and a number of domestic universities to form a joint team of "industry-University-research-medicine". Relying on the Department of Bone Oncology, Shanghai Institute of Bone Oncology, State Key Laboratory of Polymer Physics and Chemistry and other key platforms. The project aims at studying the   recurrence rate of the malignant bone and soft tissue tumors and was approved by the Ministry of Science and Technology for basic and clinical translational research  on "biomaterials for inhibiting postoperative recurrence of bone and skin tumors".

Professor Cai Zhengdong, the head of the project, introduced the project implementation plan in detail from the aspects of project background, objectives, research content, organization, assessment indicators and short-term work plan. Experts such as Professor du Jianzhong of School of Materials, Tongji University, Professor Yin Jingbo of Shanghai School of Materials, and Professor Yuan Xianyin of Shanghai Jiaotong School of Materials Science and Engineering also provided valuable suggestions for the implementation of the project.

The department of bone oncology at Shanghai General Hospital is one of the few characteristic disciplines in China which integrates the diagnosis, treatment, research and prevention of bone tumors. It has built a perfect all-dimensional scientific research platform of cellular molecule-PDX- medical-industrial cross-over-clinical trial. A series of research work has been carried out in some important directions, such as the new technology of surgical resection and reconstruction of bone tumor, the new equipment of limb salvage for children, the system construction of accurate treatment of bone tumor, the clinical research of new scheme for the treatment of advanced sarcoma and so on. In the past five years, the department has won more than 30 national key R & D projects, the National Natural Science Foundation and provincial and ministerial-level scientific research funds, including Shanghai leading talents, Shanghai Youth Top, Shanghai Silver Snake Award, Shanghai Science and Technology "Shining Star" Talent Plan, Shanghai Pujiang Talent Plan and other talent programs. The related research results around "improving the curative effect of resection and reconstruction of pelvic ring tumors" won the first prize of Science and Technology Award of Chinese Medical Association, the second prize of Shanghai Science and Technology Progress Award, etc., while the related research results of "standardized surgery and accurate treatment of osteosarcoma" won the first prize of Science and Technology Progress Award of the Ministry of Education and the second prize of Shanghai Science and Technology Progress Award. The research results were published in high-level journals such as PNAS, Nature Communication, Advanced Science, Oncogene, etc. The department has also led a number of domestic multicenter clinical studies, including the clinical trial of TILs cells in the treatment of osteosarcoma, the clinical trial of umbrella precision treatment of osteosarcoma, and the first innovative clinical study of oncolytic virus combined with TCR-T in the treatment of bone and soft tissue sarcoma, which improved the prognosis and quality of life of patients.